Lonza buys five Merck US plants. Why is it acquiring lower-margin capacity now?

Lonza Group AG (SIX: LONN) has agreed to acquire five United States contract development and manufacturing facilities from Merck KGaA, Darmstadt, Germany, more than doubling its American CDMO site count from four to nine. The transaction adds approximately 1,100 employees and specialised capabilities spanning bioconjugation, high-potency payload-linkers, viral vectors, lipid nanoparticles and aseptic fill-finish services.

The purchase price is unusually modest relative to the strategic scale. Lonza describes the enterprise value as low-to-mid triple-digit millions of Swiss francs, while management indicated it sits around the midpoint of a CHF100 million to CHF600 million range. The five facilities are expected to produce around CHF250 million of annual revenue in 2028, although margins initially will be below the Lonza group level.

That makes the acquisition less a conventional earnings purchase than a capacity-and-capability investment. Lonza is buying experienced teams, regulated facilities and specialised manufacturing technologies that can take years to create organically, then betting that its pure-play CDMO commercial organisation can improve utilisation and margins over time.

Why would Merck KGaA sell manufacturing assets that Lonza considers attractive?

The transaction reflects different strategic priorities rather than one company necessarily identifying value the other cannot see. Merck KGaA is simplifying its portfolio and focusing resources more heavily on its own Life Science and drug-development activities.

Lonza, by contrast, is a pure-play contract development and manufacturing organisation whose economics depend precisely on operating specialised facilities for other pharmaceutical and biotechnology customers. An asset that feels peripheral inside Merck can become strategically central inside Lonza.

This difference illustrates why industrial assets often change value depending on ownership. Lonza can market capacity across a broader customer base, integrate the facilities with its global manufacturing network and potentially increase utilisation beyond what Merck achieved internally.

JPMorgan analysts characterised the sale as a modest positive for Merck, while Barclays described the acquisition as strategically positive for Lonza. Both assessments can be true because each company is moving capital toward the business model it considers most attractive.

What capabilities is Lonza actually acquiring?

The St. Louis, Missouri facility adds bioconjugation capacity, an increasingly important technology for antibody-drug conjugates used in cancer treatment. ADCs connect a targeted antibody with a potent cell-killing payload, requiring highly specialised chemistry and manufacturing controls.

The Madison and Verona, Wisconsin operations specialise in high-potency payload-linkers, another critical component of ADC manufacturing. Handling highly potent compounds requires facilities, safety systems and employees with expertise that cannot be added quickly to a conventional biologics plant.

Carlsbad, California adds end-to-end viral-vector capabilities and aseptic fill-finish, strengthening Lonza’s offering for gene-therapy and cell-therapy developers. Indianapolis contributes lipid nanoparticles, liposomes and PEGylated protein solutions, broadening the group into advanced drug-delivery technologies.

The combination therefore fills several gaps simultaneously. Lonza already had substantial biologics manufacturing strength in the United States but lacked the same breadth of clinical manufacturing capability across these specialised modalities.

Why are antibody-drug conjugates strategically important to contract manufacturers?

ADCs have become one of oncology’s fastest-growing drug-development areas because they can deliver highly potent cancer-killing molecules more selectively to cells expressing specific targets. Pharmaceutical companies including AstraZeneca, Daiichi Sankyo, Pfizer and Gilead Sciences have expanded heavily in the category.

The manufacturing process is considerably more complex than producing a conventional monoclonal antibody. Companies need antibody production, linker chemistry, potent payload manufacture, conjugation and fill-finish, often with strict containment requirements.

Few pharmaceutical companies want to build every capability internally. This creates demand for CDMOs capable of handling several stages and reducing the number of suppliers involved.

Lonza’s ability to offer more of that chain can increase revenue per customer and make relationships stickier. A biotechnology company that successfully moves from clinical material into commercial manufacturing may remain with the same provider for years if quality and reliability are strong.

Why are the acquired sites initially below Lonza’s margin?

Lonza expects the facilities to generate approximately CHF250 million of 2028 sales at a CORE EBITDA margin below the group average. This suggests current utilisation, customer mix or operating efficiency is not yet at the level Lonza typically expects from mature assets.

That is not necessarily a weakness in the transaction. Underutilised specialised facilities can create attractive upside if a larger commercial organisation fills available capacity without requiring equivalent new construction spending.

Lonza explicitly says the sites contain expansion space and existing available capacity. The economic thesis is therefore based partly on using what already exists rather than funding a major greenfield programme immediately.

Management expects the assets eventually to reach peak sales and profitability around the group margin by the mid-2030s. That is a long timeline, meaning shareholders should view the acquisition as strategic infrastructure rather than a rapid earnings-accretion trade.

Why is US pharmaceutical manufacturing becoming more valuable?

The United States remains the world’s largest market for innovative medicines and is simultaneously encouraging more domestic pharmaceutical manufacturing. The Trump administration has emphasised supply-chain resilience, while major pharmaceutical companies have announced multibillion-dollar U.S. manufacturing programmes.

Drugmakers learned during the pandemic that geographically concentrated supply chains create risk, particularly for biologics, active ingredients and sterile manufacturing. Geopolitical tension has subsequently increased the value placed on domestic or allied capacity.

Lonza has been positioning aggressively around that shift. It acquired Roche’s large Vacaville biologics facility and has invested in spray-drying capacity in Oregon, while the Merck transaction adds five additional specialist sites.

This expansion gives Lonza a footprint difficult for smaller competitors to replicate. Scale alone does not guarantee high returns, but geographic breadth and specialised technologies can become powerful commercial advantages when customers want redundancy and local manufacturing.

Does the acquisition create integration risk?

Adding five plants and 1,100 employees simultaneously is a meaningful integration exercise. Each facility has existing customers, quality systems, regulatory approvals and operational processes that need to be transferred without disrupting supply.

Pharmaceutical manufacturing is less forgiving than ordinary industrial integration because changes to processes or quality systems can require regulatory review. A poorly managed transition can delay customer products or trigger compliance problems.

Lonza plans to prioritise customer continuity and employee retention immediately after closing. The experienced workforce is arguably one of the transaction’s most valuable assets because specialised pharmaceutical manufacturing depends heavily on tacit knowledge that cannot simply be recreated through equipment purchases.

The deal is expected to close around mid-2027, giving Merck and Lonza time to manage the transfer. Until then, the businesses remain independent and the forecast revenue should not be treated as already consolidated into Lonza’s accounts.

Why is Lonza funding the deal with cash and existing credit?

The transaction is modest enough relative to Lonza’s scale that management expects to use cash on hand and existing credit facilities while retaining its BBB+ credit rating. This avoids equity dilution and allows the company to proceed with its separately announced share-buyback plans.

That financing structure supports the argument that the acquisition is financially manageable. A much larger debt-funded transaction would raise questions about leverage at the same time Lonza is investing in Vacaville and other capacity.

The main capital-allocation risk instead comes from cumulative investment. Building a wider U.S. network requires not only purchase consideration but future capital expenditure to modernise and expand individual sites.

Management says additional spending will follow market demand rather than being committed automatically. This discipline matters because unused pharmaceutical capacity can produce poor returns even when the underlying technology is attractive.

Could Lonza become the biggest beneficiary of pharma manufacturing outsourcing?

Pharmaceutical companies increasingly concentrate on discovery, clinical development and commercialisation while outsourcing parts of manufacturing to specialised providers. Complex biologics, ADCs, cell and gene therapies strengthen this trend because each new modality requires dedicated expertise and infrastructure.

Lonza already has one of the broadest global CDMO networks, giving it the ability to support programmes from early development through commercial manufacturing. The Merck sites expand that end-to-end model further inside the United States.

Competition remains strong from companies including Catalent under Novo Holdings, Samsung Biologics and Thermo Fisher Scientific. Customers also avoid relying entirely on one manufacturer, meaning scale does not translate automatically into monopoly economics.

Lonza’s advantage will depend on execution, regulatory performance and capacity utilisation rather than the number of facilities alone. The most valuable network is the one customers trust to deliver critical therapies consistently.

What should investors watch after the Merck transaction closes?

Revenue conversion provides the first benchmark because management expects approximately CHF250 million from the sites in 2028. Performance above that level would indicate successful customer retention and new business wins.

Margin progression is more important over time. The acquisition becomes much more valuable if existing capacity fills and profitability approaches Lonza’s broader group economics without excessive additional capital spending.

Demand in ADCs, viral vectors and advanced delivery technologies provides the third test. These categories are attractive today, but biotechnology cycles can change rapidly and some therapeutic modalities may grow more slowly than currently anticipated.

Lonza is not paying a blockbuster acquisition price for the Merck network. It is making a relatively modest financial commitment to obtain infrastructure and expertise that would be expensive and slow to build from scratch. The real investment question is therefore not whether the purchase price looks cheap, but whether Lonza can transform underused specialist assets into a high-margin extension of its U.S. pharmaceutical manufacturing platform.